Efficacy of sustained combination therapy for at least 6 months with thiopurines and infliximab in patients with ulcerative colitis in clinical remission: A retrospective multicenter French experience

Journal of Crohn's and Colitis

Volumn 9, Issue 3, 2015, Pages 252-258

  Filippi, J ^a   Laharie, D ^b   Michiels, C ^c   Flamand, M ^d   Bouguen, G ^e   Nancey, S ^f   Presles, E ^g   Paul, S ^a   Schneider, S ^a   Hebuterne X ^a   Roblin, X ^g  

^a UNIVERSITY HOSPITAL OF NICE   (France)

^b BORDEAUX UNIVERSITY HOSPITAL   (France)

^c DIJON UNIVERSITY HOSPITAL   (France)

^d NANTES UNIVERSITY HOSPITAL   (France)

^e RENNES UNIVERSITY HOSPITAL   (France)

^f CENTRE HOSPITALIER LYON SUD   (France)

^g UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

Author keywords

Azathioprine; Combotherapy; Infliximab; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; INFLIXIMAB; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; COLON RESECTION; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ACTIVITY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REMISSION; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SEX RATIO; TREATMENT DURATION; ULCERATIVE COLITIS; CLINICAL TRIAL; COLITIS, ULCERATIVE; DRUG ADMINISTRATION; DRUG COMBINATION; FRANCE; INDUCTION CHEMOTHERAPY; KAPLAN MEIER METHOD; MAINTENANCE CHEMOTHERAPY; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME;

ADULT; AZATHIOPRINE; COLITIS, ULCERATIVE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; FRANCE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INDUCTION CHEMOTHERAPY; INFLIXIMAB; KAPLAN-MEIER ESTIMATE; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; ROC CURVE; TREATMENT OUTCOME;

EID: 84945247207     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1093/ecco-jcc/jjv001     Document Type: Article

References (21)

1. Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008;6:644-53
2. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76
3. Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol 2011;106:685-98
4. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-8
5. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine or combination therapy for Crohn's disease. N Engl J Med 2010;362:1383-95
6. Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014;146:392-400
7. Oussalah A, Chevaux JB, Fay R, Sandborn WJ, Bigard MA, Peyrin-Biroulet L. Predictors of infliximab failure after azathioprine withdrawal in Crohn's disease treated with combination therapy. Am J Gastroenterol 2010;105:1142-9
8. Sokol H, Seksik P, Carrat F, et al. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut 2010;59:1363-8
9. Bouguen G, Siproudhis L, Gizard E, et al. Long-term outcome of perianal fistulizing Crohn's disease treated with infliximab. Clin Gastroenterol Hepatol 2013;11:975-81
10. Kestens C, van Oijen MG, Mulder CL, et al. Adalimumab and infliximab are equally effective for Crohn's disease in patients not previously treated with anti-tumor necrosis factor-a agents. Clin Gastroenterol Hepatol 2013;11:826-31
11. Van Assche G, Magdelaine-Beuzelin C, D'Haens G, et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008;134:1861-8
12. Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008;134:929-36
13. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 1989;170:2-6; discussion 16-19
14. Oussalah A, Evesque L, Laharie D, et al. A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization. Am J Gastroenterol 2010;105:2617-25
15. Ferrante M, Vermeire S, Fidder H, et al. Long-term outcome after infliximab for refractory ulcerative colitis. J Crohns Colitis 2008;2:219-25
16. Armuzzi A, Pugliese D, Danese S, et al. Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis. Inflamm Bowel Dis 2014;20:1368-74
17. Dulai PS, Siegel CA, Colombel JF, Sandborn WJ, Peyrin-Biroulet L. Systematic review: monotherapy with antitumour necrosis factor alpha agents versus combination therapy with an immunosuppressive for IBD. Gut 2014 (in press)
18. Ungar B, Chowers Y, Yavzori M, et al. The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. Gut 2014 (in press)
19. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005;19 suppl A:5A-36A
20. Drobne D, Bossuyt P, Breynaert C, et al. Withdrawal of immunomodulators after co-treatment does not reduce trough level of infliximab in patients with Crohn's disease. Clin Gastroenterol Hepatol 2014 (in press)
21. Arias MT, Vande Casteele N, Vermeire S, et al. A panel to predict longterm outcome of infliximab therapy for patients with ulcerative colitis. Clin Gastroenterol Hepatol 2014 (in press)